Related Experiment Video
Updated: Sep 20, 2025

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
Published on: June 14, 2016
Late-onset Fabry disease: the cardiac sequela
John Tremblay1, Samuel Kim2, Edward Philbin2
1Internal Medicine, Albany Medical Center, Albany, New York, USA tremblj2@amc.edu.
Insights
Fabry disease (FD) can present late with cardiac issues like atrial fibrillation and hypertrophic cardiomyopathy, mimicking other conditions. Early recognition of systemic symptoms is crucial for timely FD diagnosis and treatment.
Area of Science:
- Cardiology
- Genetics
- Rare Diseases
Background:
- Fabry disease (FD) is a rare genetic disorder.
- Late-onset FD phenotypes can be challenging to diagnose.
- Cardiac manifestations are common in FD.
Observation:
- A patient presented with atrial fibrillation and left ventricular hypertrophy (LVH) mimicking hypertrophic cardiomyopathy.
- Over 14 years, he developed heart failure, kidney disease, neuropathy, hearing loss, and GI symptoms.
- A c.146 G>C GLA variant was identified, confirming late-onset FD.
Findings:
- The patient's constellation of symptoms led to FD diagnosis through enzyme activity and genetic testing.
- Endomyocardial biopsy confirmed FD.
- Enzyme replacement therapy was initiated.
Implications:
- This case highlights the importance of considering FD in patients with unexplained LVH and systemic symptoms.
- Early diagnosis of FD is critical for effective management and preventing disease progression.
- Meticulous attention to cardiac 'red flags' can aid in early FD detection.
Abstract:
We describe a patient with Fabry disease (FD) who initially presented with atrial fibrillation without left ventricular hypertrophy (LVH) 14 years before being correctly diagnosed with FD. In the interim, he survived a myocardial infarction complicated by ventricular fibrillation, and his severe LVH was misdiagnosed as sarcomeric hypertrophic cardiomyopathy. In the following 4 years, he developed proteinuric kidney disease, neuropathy, sensorineural hearing loss and gastrointestinal symptoms. The patient was eventually readmitted for an overt heart failure (HF) exacerbation and was seen by an HF cardiologist. The constellation of systemic findings led to further diagnostic testing, including an endomyocardial biopsy, tests to determine alpha-galactosidase A enzyme activity and α-galactosidase A gene (GLA) analysis. The results of the patient's tests were consistent with FD and he was started on enzyme replacement therapy. To our knowledge, this is the first detailed description of a late-onset phenotype of FD with c.146 G>C GLA variant. In addition, this case serves as a potent reminder to pay meticulous attention to 'red flags' accompanying LVH.
More Related Videos
08:38Author Spotlight: A Neonatal Heterotopic Rat Heart Transplantation Model for the Study of Endothelial-to-Mesenchymal Transition
Published on: July 21, 2023
09:40Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle
Published on: January 19, 2017
Related Concept Videos
Rheumatic Heart Disease I: Introduction
Pathophysiology of Heart Failure
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy I: Introduction and Classification
Heart Failure II: Pathophysiology
Cardiomyopathy III: Hypertrophic Cardiomyopathy